NCT02423200已完成2 期
A Randomized, Open-Label, Multiple Dose Clinical Pharmacology Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or With Mild AD
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines
研究概览
简要总结
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD. The study will also evaluate the safety and tolerability of VX-745 in these patients during 6 weeks of dosing, as well as the plasma and cerebrospinal fluid concentrations of VX-745 during dosing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 60 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 60 - 85 (inclusive)
- •Willing and able to provide informed consent
- •Clinical presentation consistent with MCI due to AD or of mild AD
- •Gradual progressive decline in memory function over >6 months
- •Amnestic presentation on neuropsychological testing with rapid forgetting (% reduction 1.5 standard deviations below the mean)
- •Clinical Dementia Rating (CDR) Sum of Box (SOB) score ≥0.5
- •Mini-Mental State Examination (MMSE) range: 20 to 30
- •Brain hypometabolism by 18F-2-fluoro-2-deoxyglucose (FDG)-PET
- •Participants may be taking medications for AD, provided that the dose of these medications has been stable for >3 months.
排除标准
- •Evidence of neurodegenerative disease other than AD
- •Inability for any reason to undergo MRI scans (e.g. pacemaker, vascular stent or stent graft). Patients who require sedation for screening procedures such as MRI may receive a short-acting sedative.
- •Psychiatric disorder that would compromise ability to comply with study requirements
- •History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years
- •Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder or metabolic/endocrine disorders or other disease that would preclude treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy
- •Recent (<90 days) changes to AD medications prescribed for cognitive reasons or with the potential to impact cognition
- •Psychotropic drugs taken within 1 month. Anticoagulant drugs taken within 1 week.
- •Participation in a study of an investigational drug less than 6 months or 5 half-lives of the investigational drug, whichever is longer, before enrollment in the study
- •Male subjects with female partner of child-bearing potential who are unwilling or unable to adhere to contraception requirements
- •Female subjects who have not reached menopause or have not had a hysterectomy or bilateral oophorectomy/salpingoophorectomy
- •Positive urine or serum pregnancy test or plans desires to become pregnant during the course of the trial
- •Donation of >500 mL of blood or blood products within 2 months
- •History of alcohol and/or illicit drug abuse within 6 months.
- •Infection with hepatitis A, B or C or HIV.
- •Any factor deemed by the investigator to be likely to interfere with study conduction
研究组 & 干预措施
VX-745 dose level 1
Experimental
Active Group 1: VX-745 dose level 1 twice daily
干预措施: VX-745 (Drug)
VX-745 dose level 2
Experimental
Active Group 1: VX-745 dose level 2 twice daily
干预措施: VX-745 (Drug)
结局指标
主要结局
Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines
时间窗: Baseline and Day 42 of dosing with VX-745
Cytokines: Of nine cytokines assessed, only CSF IL-8 quantifiable at all time points. And so, only IL-8 levels are being reported herein. The analysis was exploratory and no statistical analysis was performed.
次要结局
- Severe or Serious Adverse Events(At baseline and at each study visit during (days 1, 7, 14, 21, 28, 35 and 42) and after (day 51) dosing)
- Maximal CSF VX-745 Concentration(All samples with quantifiable CSF drug levels were included (n=12). Eight were obtained 3-hours post-dose, either on Day 1 (n=4) or Day 42 (n=4). 3 samples were at 6-hours post-dose on Day 42; and one was at 6-hours post-dose on Day 1.)
- Episodic Memory Function(Change from baseline to Day 42)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial EpilepsyEpilepsyNCT01501383Vertex Pharmaceuticals Incorporated55
已完成
2 期
Study of VX-765 in Subjects With Treatment-resistant Partial EpilepsyPartial EpilepsyNCT01048255Vertex Pharmaceuticals Incorporated60
已完成
1 期
A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy ParticipantsPainNCT05818852Vertex Pharmaceuticals Incorporated72
已完成
2 期
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)Painful Lumbosacral RadiculopathyNCT06176196Vertex Pharmaceuticals Incorporated218
已完成
2 期
A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702Rheumatoid ArthritisNCT00395577Vertex Pharmaceuticals Incorporated120